Robert Graham Susman - 07 Apr 2026 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Director
Issuer ticker: IMVT
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 16:22:29 UTC
Prior SEC filing: 05 May 2025
Next SEC filing: 01 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Tiago Girao, Attorney-in-Fact for Robert Susman

Key filing fact

Robert Graham Susman filed Form 4 for Immunovant, Inc. (IMVT) on 09 Apr 2026.

Key facts

This page summarizes Robert Graham Susman's Form 4 filing for Immunovant, Inc. (IMVT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Apr 2026, 16:22.

Change

Previous filing in this sequence was filed on 05 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002065992 Primary reporting owner

Susman Robert Graham

Relationship: Director
Address: C/O IMMUNOVANT, INC., 1000 PARK FORTY PLAZA, SUITE 210, DURHAM
Signature: /s/ Tiago Girao, Attorney-in-Fact for Robert Susman
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Award

Transaction value
Shares: +13,880
Change %: +55%
Price: $0.000000^*
Shares after: 38,896
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +7,061
Change %
Price: $0.000000^*
Shares after: 7,061
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,061
Exercise price: $24.61
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Footnote F2

These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.